Program
HRS-7085
A development code. Also written as “HRS-7085 tablets” and “HRS-7085 Tablets”.
In Jiangsu HengRui Medicine's pipeline, miR 124
. Its studies are mostly in Colitis, Ulcerative · Inflammatory Bowel Diseases, led by Jiangsu HengRui Medicine.
Furthest: phase 2, since Sep 29, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 43 open or running | phase 2since Sep 29, 2025 | Nov 27, 2022 | Dec 2026phase 2 · NCT07229950 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-7085
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2022First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT05638347 · 16 enrolled · Australia
- Dec 10, 2023Phase 1 study in Inflammatory Bowel DiseasesNCT06175949 · 70 planned
- Sep 29, 2025Phase 2 study in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT07229950 · 48 planned · China
- Jul 31, 2026Phase 1 study in Moderate to Severe Ulcerative ColitisNCT07760831 · 8 planned · Moldova
Ahead
- Dec 2026Primary completion: phase 2 study in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT07229950
- Apr 2027Primary completion: phase 1 study in Moderate to Severe Ulcerative ColitisNCT07760831
TargetBeta
“miR 124”the company's pipeline, read by Claude · source
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07760831Moderate to Severe Ulcerative Colitis · Moldova | 1 | Not yet recruiting | Apr 2027 | 8 |
| NCT07229950Adult Patients With Moderately to Severely Active Ulcerative Colitis · China | 2 | Recruiting | Dec 2026 | 48 |
| NCT06175949Inflammatory Bowel Diseases | 1 | Not yet recruiting | Jun 2024 | 70 |
| NCT05638347Inflammatory Bowel Diseases · Australia | 1 | Completed | Mar 16, 2023 | 16 |
How it is read
Names in the registry
- “HRS-7085 tablets”, 2 entries
- “HRS-7085”, 2 entries
- “HRS-7085 Tablets”, 1 entry
Codes read as this program: HRS7085.
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 2 studies
- Inflammatory Bowel Diseases, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.